Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Vaxcyte, Inc.PCVX · Entity 1164 | PRESIDENT AND CFO | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Vaxcyte, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,316 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 7,155 · Balance 95,316 F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 61,850 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 61,850 F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs.
F2: Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dermira, Inc.
Report date February 20, 2020 · Filed February 25, 2020
Section 16 reporting ended · disclosed 2020-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 1
1 source rowRow 1 · 2020-02-20 · Disposition to issuer · Disposed 41,951 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.51 · Expires 2024-06-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-20 · Disposition to issuer · Disposed 120.513 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-20 · Disposition to issuer · Disposed 73,287 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2024-10-01 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-20 · Disposition to issuer · Disposed 67,240 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.37 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.84 · Expires 2027-02-16 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-20 · Disposition to issuer · Disposed 71,250 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.25 · Expires 2028-02-15 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-02-20 · Disposition to issuer · Disposed 57,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Employee Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.42 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-02-20 · Disposition to issuer · Disposed 65,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-02-20 · Disposition to issuer · Disposed 3,562 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-02-20 · Disposition to issuer · Disposed 5,700 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-02-20 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-02-20 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price. F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 10, 2020, by and among Dermira, Inc. ("Dermira"), Eli Lilly and Company, an Indiana corporation ("Lilly"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the "Merger"), effective as of February 20, 2020. Pursuant to the Merger Agreement, each issued and outstanding share (the "Shares") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Includes 1,024 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time.
F4: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit ("RSU"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · derivative · entry 9 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: Fully vested on August 15, 2019. F5 · derivative.expiration_date: Fully vested on August 15, 2019. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 2,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · derivative · entry 8 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Underlying: Common Stock · 2,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2018 and 30% of the shares on August 15, 2019. 30% of the shares will vest on each of August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F4 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2018 and 30% of the shares on August 15, 2019. 30% of the shares will vest on each of August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · derivative · entry 7 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 Underlying: Common Stock · 3,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on each of August 15, 2018 and August 15, 2019. The remaining 30% of the shares will vest on August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F3 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on each of August 15, 2018 and August 15, 2019. The remaining 30% of the shares will vest on August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 1,232 | $7.91 | $9,745.12 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,927 Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 1,233 | $7.91 | $9,753.03 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,159 Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 986 | $7.91 | $7,799.26 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,392 Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,816 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 20, 2019 01:48 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 2,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-004388 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:03 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003027 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: Vests as to 50% of the shares on each of May 17, 2019 and May 17, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F3 · derivative.expiration_date: Vests as to 50% of the shares on each of May 17, 2019 and May 17, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:03 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 8,645 | $10.50 | $90,772.50 |
DisclosureSEC source: 0001562180-19-003027 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,403 Read SEC document |
| May 17, 2019 Filed May 21, 2019 20:03 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003027 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| February 12, 2019 Filed Feb 15, 2019 00:57 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-000998 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date. F4 · derivative.expiration_date: Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 12, 2019 Filed Feb 15, 2019 00:57 UTC | Dermira, Inc. DERM · Entity 11896 | GrantEmployee Stock Options (Right to buy) · Derivative | 65,000 | $0.00 Strike: $7.42 | $0.00 |
DisclosureSEC source: 0001562180-19-000998 · primarydocument.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-02-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on February 1, 2019, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · derivative · entry 10 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,562 Underlying: Common Stock · 3,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F6 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on each of August 15, 2017 and August 15, 2018. The remaining 30% of the shares will vest on August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the vesting date. F6 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on each of August 15, 2017 and August 15, 2018. The remaining 30% of the shares will vest on August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · derivative · entry 9 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F5 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F5 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · derivative · entry 8 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,550 Underlying: Common Stock · 950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019, August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F4 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019, August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · derivative · entry 7 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: Vests as to 50% of the shares on each of May 17, 2019 and May 17, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F3 · derivative.expiration_date: Vests as to 50% of the shares on each of May 17, 2019 and May 17, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 1,233 | $9.58 | $11,812.14 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,496 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 1,232 | $9.58 | $11,802.56 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,729 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 329 | $9.58 | $3,151.82 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,961 Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 20:05 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 950 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-003669 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:37 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 9,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-001047 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vests as to 10% of the shares on August 15, 2018, 30% on August 15, 2019, 30% on August 15, 2020, 30% on August 15,2021, subject to the continuing employment of the Reporting Person on each vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:37 UTC | Dermira, Inc. DERM · Entity 11896 | GrantEmployee Stock Options (Right to buy) · Derivative | 57,000 | $28.25 Strike: $28.25 | $1,610,250.00 |
DisclosureSEC source: 0001562180-18-001047 · primarydocument.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2028-02-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on January 1, 2018, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · derivative · entry 6 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 3,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on August 15, 2017. 30% of the shares will vest on each of August 15, 2018 and August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F4 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on August 15, 2017. 30% of the shares will vest on each of August 15, 2018 and August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionRestricted Stock Unit · Derivative | 1,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · derivative · entry 5 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,687 Underlying: Common Stock · 1,188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F3 · derivative.exercise_date: Vested as to 10% of the shares on August 15, 2017. 30% of the shares will vest on each of August 15, 2018, August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. F3 · derivative.expiration_date: Vested as to 10% of the shares on August 15, 2017. 30% of the shares will vest on each of August 15, 2018, August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 447 | $23.58 | $10,540.26 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · nonDerivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,073 Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Tax withholdingCommon Stock | 1,339 | $23.58 | $31,573.62 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,520 Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 1,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 23:45 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 3,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002759 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:25 UTC | Dermira, Inc. DERM · Entity 11896 | GrantRestricted Stock Unit · Derivative | 11,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-000857 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,875 Underlying: Common Stock · 11,875 shares Expires not disclosed F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of DERM common stock. F4 · derivative.exercise_date: Vests as to 10% of the shares on August 15, 2017, 30% on August 15, 2018, 30% on August 15, 2019, 30% on August 15,2020, subject to the continuing employment of the Reporting Person on each vesting date. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of DERM common stock. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 21:25 UTC | Dermira, Inc. DERM · Entity 11896 | GrantEmployee Stock Options (Right to buy) · Derivative | 71,250 | $33.84 Strike: $33.84 | $2,411,100.00 |
DisclosureSEC source: 0001562180-17-000857 · primarydocument.xml · derivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2027-02-16 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on February 1, 2017, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:02 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionEmployee Stock Options (Right to buy) · Derivative | 4,100 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-16-003452 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,513 Underlying: Common Stock · 4,100 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total shares underlying the option vested and became exercisable on May 1, 2015 and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:02 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 4,100 | $35.02 | $143,582.00 |
DisclosureSEC source: 0001562180-16-003452 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,116 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 21:02 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 4,100 | $5.51 | $22,591.00 |
DisclosureSEC source: 0001562180-16-003452 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 19:28 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionEmployee Stock Options (Right to buy) · Derivative | 10,900 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-16-003239 · primarydocument.xml · derivative · entry 4 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,613 Underlying: Common Stock · 10,900 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the total shares underlying the option vested and became exercisable on May 1, 2015 and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 19:28 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 1,605 | $35.13 | $56,383.65 |
DisclosureSEC source: 0001562180-16-003239 · primarydocument.xml · nonDerivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,116 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.99 to $35.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 19:28 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 9,295 | $34.20 | $317,889.00 |
DisclosureSEC source: 0001562180-16-003239 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,721 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.92 to $34.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 19:28 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 10,900 | $5.51 | $60,059.00 |
DisclosureSEC source: 0001562180-16-003239 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 20:14 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionEmployee Stock Options (Right to buy) · Derivative | 15,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-16-003153 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,513 Underlying: Common Stock · 15,000 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total shares underlying the option vested and became exercisable on May 1, 2015 and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 20:14 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 15,000 | $35.01 | $525,150.00 |
DisclosureSEC source: 0001562180-16-003153 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,116 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $35.00 to $35.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| September 19, 2016 Filed Sep 20, 2016 20:14 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 15,000 | $5.51 | $82,650.00 |
DisclosureSEC source: 0001562180-16-003153 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 13:14 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionEmployee Stock Options (Right to buy) · Derivative | 10,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001562180-16-003141 · primarydocument.xml · derivative · entry 3 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,513 Underlying: Common Stock · 10,000 shares Expires 2024-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the total shares underlying the option vested and became exercisable on May 1, 2015 and 1/48 of the total shares underlying the option vest and become exercisable each month thereafter, subject to the continuing employment of the Reporting person on the applicable vesting date. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 13:14 UTC | Dermira, Inc. DERM · Entity 11896 | SaleCommon Stock | 10,000 | $32.53 | $325,300.00 |
DisclosureSEC source: 0001562180-16-003141 · primarydocument.xml · nonDerivative · entry 2 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,116 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.30 to $32.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: These shares include prior ESPP purchases. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 13:14 UTC | Dermira, Inc. DERM · Entity 11896 | Exercise / conversionCommon Stock | 10,000 | $5.51 | $55,100.00 |
DisclosureSEC source: 0001562180-16-003141 · primarydocument.xml · nonDerivative · entry 1 GUGGENHIME ANDREW · CIK 0001230724 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.